Management of Chronic Myelogenous Leukemia with COVID-19 and Hepatitis B

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Aug 21

PMID 37601670

Authors

Tian Yu

Weiming Li

Tao Yu

Affiliations

Soon will be listed here.

Abstract

The application of immunosuppressive agents and targeted drugs has opened a novel approach for the treatment of hematological tumors, and the application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia is one of the landmark breakthroughs that has considerably improved the prognosis of CML patients. However, with the extensive use of TKI, the co-infection of CML patients has become increasingly apparent, especially regarding infectious diseases such as hepatitis B and COVID-19. The underlying mechanism may be related to the inhibition of the immune function by TKI. Poor management, including disease progression due to the infectious disease or TKI dose reduction or discontinuation, may lead to adverse clinical outcomes and can even be life-threatening. Therefore, this review principally provides an overview of the pathogenesis and standardized management principles of CML patients with comorbid COVID-19 or hepatitis B in order to improve clinicians' awareness of the risks so as to more effectively diagnose and treat CML and improve the survival rate and quality of life of patients. In the past two decades, owing to the advent of imatinib, chronic myeloid leukemia (CML) has transformed into a chronic controllable disease, and even treatment-free remission can be anticipated. Earlier studies have indicated that tyrosine kinase inhibitor (TKI) exerts a peculiar inhibitory effect on the body's immune function. Therefore, with the widespread application of TKI, more and more attention has been paid to the comorbidity of infectious diseases in CML patients, especially in patients with progressive disease or non-remission. Despite some studies revealing that the proportion and severity of SARS-CoV-2 infection in CML patients receiving TKI treatment are lower than in patients with other hematological malignancies, CML patients with stable disease are still recommended to be vaccinated against SARS-CoV-2, while TKI may or may not be discontinued. Meanwhile, the management of CML patients during the epidemic of coronavirus disease 2019 (COVID-19) still necessitates further discussion. This article also provides an overview of TKI-related hepatitis B reactivation. If not managed, patients may face adverse consequences such as hepatitis B reactivation-related hepatitis, liver failure, and progression of CML after forced withdrawal of medication. Therefore, this review aimed to comprehensively describe the management of CML patients with comorbid COVID-19, the pathogenesis of hepatitis B reactivation, the indicated population for prophylactic antiviral therapy, the time of antiviral drug discontinuation, and drug selection.

References

Asif M, Amir M, Hussain A, Achakzai N, Pushparaj P, Rasool M . Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review. Medicine (Baltimore). 2022; 101(26):e29660. PMC: 9239670. DOI: 10.1097/MD.0000000000029660. View

Ector G, Huijskens E, Blijlevens N, Westerweel P . Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study. Leukemia. 2020; 34(9):2533-2535. PMC: 7341464. DOI: 10.1038/s41375-020-0964-0. View

Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K . Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV.... Transpl Infect Dis. 2014; 16(5):797-801. DOI: 10.1111/tid.12283. View

Climent N, Plana M . Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Front Pharmacol. 2019; 10:1232. PMC: 6813222. DOI: 10.3389/fphar.2019.01232. View

Bonifacio M, Tiribelli M, Miggiano M, Abruzzese E, Binotto G, Scaffidi L . The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population. Cancer Med. 2021; 10(18):6310-6316. PMC: 8446554. DOI: 10.1002/cam4.4179. View

Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet. 2007; 370(9584):342-50. DOI: 10.1016/S0140-6736(07)61165-9. View

Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk E . Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology. 2017; 66(2):379-388. PMC: 6485929. DOI: 10.1002/hep.29082. View

Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y . American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2014; 148(1):215-9. DOI: 10.1053/j.gastro.2014.10.039. View

Lai G, Yan S, Chang C, Tsai C . Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013; 19(8):1318-21. PMC: 3587491. DOI: 10.3748/wjg.v19.i8.1318. View

10.

Lu G, Ling Y, Jiang M, Tan Y, Wei D, Jiang L . Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. Front Med. 2023; 17(4):758-767. PMC: 10064619. DOI: 10.1007/s11684-022-0981-7. View

11.

Claudiani S, Apperley J, Parker E, Marchesin F, Katsanovskaja K, Palanicawandar R . Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. Br J Haematol. 2021; 197(1):e1-e4. DOI: 10.1111/bjh.18001. View

12.

Wang Y, Liang J, Sheng W, Tien F, Chen C, Tien H . Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-Experience in 142 adult patients with chronic myeloid leukemia. Leuk Res. 2019; 81:95-97. DOI: 10.1016/j.leukres.2019.05.001. View

13.

Li W, Wang D, Guo J, Yuan G, Yang Z, Gale R . COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020; 34(7):1799-1804. PMC: 7233329. DOI: 10.1038/s41375-020-0853-6. View

14.

Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M . Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015; 102(3):379-82. DOI: 10.1007/s12185-015-1788-y. View

15.

Sora F, Ponziani F, Laurenti L, Chiusolo P, Autore F, Gasbarrini A . Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2016; 58(4):993-995. DOI: 10.1080/10428194.2016.1219906. View

16.

Recoche I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F . Drug-drug interactions with imatinib: An observational study. Medicine (Baltimore). 2016; 95(40):e5076. PMC: 5059082. DOI: 10.1097/MD.0000000000005076. View

17.

Mohty M, Jourdan E, Mami N, Vey N, Damaj G, Blaise D . Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood. 2004; 103(12):4666-8. DOI: 10.1182/blood-2003-09-3220. View

18.

Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K . Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2005; 47(1):155-7. DOI: 10.1080/14639230500236818. View

19.

Cheng F, Xiang H, Gale R, Chen S, Qu J, Guo H . SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia. J Cancer Res Clin Oncol. 2023; 149(13):11025-11030. DOI: 10.1007/s00432-023-04995-6. View

20.

Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J . APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021; 15(5):1031-1048. PMC: 8382940. DOI: 10.1007/s12072-021-10239-x. View